These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

212 related articles for article (PubMed ID: 23040786)

  • 1. Assessing efficacy of indacaterol in moderate and severe COPD patients: a 12-week study in an Asian population.
    To Y; Kinoshita M; Lee SH; Hang LW; Ichinose M; Fukuchi Y; Kitawaki T; Okino N; Prasad N; Lawrence D; Kramer B
    Respir Med; 2012 Dec; 106(12):1715-21. PubMed ID: 23040786
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Efficacy and safety of indacaterol 150 and 300 µg in chronic obstructive pulmonary disease patients from six Asian areas including Japan: a 12-week, placebo-controlled study.
    Kinoshita M; Lee SH; Hang LW; Ichinose M; Hosoe M; Okino N; Prasad N; Kramer B; Fukuchi Y;
    Respirology; 2012 Feb; 17(2):379-89. PubMed ID: 22122202
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Efficacy and tolerability of indacaterol 75 μg once daily in patients aged ≥40 years with chronic obstructive pulmonary disease: results from 2 double-blind, placebo-controlled 12-week studies.
    Kerwin EM; Gotfried MH; Lawrence D; Lassen C; Kramer B
    Clin Ther; 2011 Dec; 33(12):1974-84. PubMed ID: 22177371
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Effects of long-acting bronchodilators in COPD patients according to COPD severity and ICS use.
    Decramer M; Dahl R; Kornmann O; Korn S; Lawrence D; McBryan D
    Respir Med; 2013 Feb; 107(2):223-32. PubMed ID: 23219347
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Efficacy of indacaterol 75 μg once-daily on dyspnea and health status: results of two double-blind, placebo-controlled 12-week studies.
    Gotfried MH; Kerwin EM; Lawrence D; Lassen C; Kramer B
    COPD; 2012 Dec; 9(6):629-36. PubMed ID: 23020650
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Once-daily bronchodilators for chronic obstructive pulmonary disease: indacaterol versus tiotropium.
    Donohue JF; Fogarty C; Lötvall J; Mahler DA; Worth H; Yorgancioglu A; Iqbal A; Swales J; Owen R; Higgins M; Kramer B;
    Am J Respir Crit Care Med; 2010 Jul; 182(2):155-62. PubMed ID: 20463178
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Efficacy and safety of indacaterol and tiotropium in COPD patients according to dyspnoea severity.
    Mahler DA; Buhl R; Lawrence D; McBryan D
    Pulm Pharmacol Ther; 2013 Jun; 26(3):348-55. PubMed ID: 23434446
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Blinded 12-week comparison of once-daily indacaterol and tiotropium in COPD.
    Buhl R; Dunn LJ; Disdier C; Lassen C; Amos C; Henley M; Kramer B;
    Eur Respir J; 2011 Oct; 38(4):797-803. PubMed ID: 21622587
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Indacaterol therapy in patients with COPD not receiving other maintenance treatment.
    Decramer M; Rossi A; Lawrence D; McBryan D
    Respir Med; 2012 Dec; 106(12):1706-14. PubMed ID: 23031496
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Inhaled indacaterol for the treatment of COPD patients with destroyed lung by tuberculosis and moderate-to-severe airflow limitation: results from the randomized INFINITY study.
    Kim CJ; Yoon HK; Park MJ; Yoo KH; Jung KS; Park JW; Lim SY; Shim JJ; Lee YC; Kim YS; Oh YM; Kim S; Yoo CG
    Int J Chron Obstruct Pulmon Dis; 2017; 12():1589-1596. PubMed ID: 28615931
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Once-daily indacaterol versus twice-daily salmeterol for COPD: a placebo-controlled comparison.
    Kornmann O; Dahl R; Centanni S; Dogra A; Owen R; Lassen C; Kramer B;
    Eur Respir J; 2011 Feb; 37(2):273-9. PubMed ID: 20693243
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Profiling the effects of indacaterol on dyspnoea and health status in patients with COPD.
    Jones PW; Mahler DA; Gale R; Owen R; Kramer B
    Respir Med; 2011 Jun; 105(6):892-9. PubMed ID: 21397482
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Efficacy and safety of indacaterol in patients with chronic obstructive pulmonary disease aged over 65 years: A pooled analysis.
    Girodet PO; Jasnot JY; Le Gros V; Decuypère L; Cao W; Devouassoux G
    Respir Med; 2017 Jul; 128():92-101. PubMed ID: 28566230
    [TBL] [Abstract][Full Text] [Related]  

  • 14. The impact of treatment with indacaterol in patients with COPD: A post-hoc analysis according to GOLD 2011 categories A to D.
    Kerstjens HA; Deslée G; Dahl R; Donohue JF; Young D; Lawrence D; Kornmann O
    Pulm Pharmacol Ther; 2015 Jun; 32():101-8. PubMed ID: 25743376
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Effect of once-daily indacaterol in a predominantly Chinese population with chronic obstructive pulmonary disease: a 26-week Asia-Pacific study.
    Yao W; Wang C; Zhong N; Han X; Wu C; Yan X; Chen P; Yang W; Henley M; Kramer B
    Respirology; 2014 Feb; 19(2):231-238. PubMed ID: 24383720
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Once-daily indacaterol versus tiotropium for patients with severe chronic obstructive pulmonary disease (INVIGORATE): a randomised, blinded, parallel-group study.
    Decramer ML; Chapman KR; Dahl R; Frith P; Devouassoux G; Fritscher C; Cameron R; Shoaib M; Lawrence D; Young D; McBryan D;
    Lancet Respir Med; 2013 Sep; 1(7):524-33. PubMed ID: 24461613
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Sustained 24-hour efficacy of once daily indacaterol (300 μg) in patients with chronic obstructive pulmonary disease: a randomized, crossover study.
    Laforce C; Aumann J; de Teresa Parreño L; Iqbal A; Young D; Owen R; Higgins M; Kramer B;
    Pulm Pharmacol Ther; 2011 Feb; 24(1):162-8. PubMed ID: 20619353
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Safety, tolerability and efficacy of indacaterol, a novel once-daily beta(2)-agonist, in patients with COPD: a 28-day randomised, placebo controlled clinical trial.
    Beier J; Chanez P; Martinot JB; Schreurs AJ; Tkácová R; Bao W; Jack D; Higgins M
    Pulm Pharmacol Ther; 2007; 20(6):740-9. PubMed ID: 17088091
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Efficacy of a new once-daily long-acting inhaled beta2-agonist indacaterol versus twice-daily formoterol in COPD.
    Dahl R; Chung KF; Buhl R; Magnussen H; Nonikov V; Jack D; Bleasdale P; Owen R; Higgins M; Kramer B;
    Thorax; 2010 Jun; 65(6):473-9. PubMed ID: 20522841
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Indacaterol 75 μg once daily for the treatment of patients with chronic obstructive pulmonary disease: a North American perspective.
    Kerwin EM; Williams J
    Ther Adv Respir Dis; 2013 Feb; 7(1):25-37. PubMed ID: 23296242
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 11.